Azvudine

阿兹夫定

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameAzvudine
Drug Alias Name阿滋福啶捷倍安FNCRO-0622HY-19314 +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsVirion infectivity factor inhibitorsRNA-directed RNA polymerase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseVirion infectivity factorRNA-directed RNA polymerase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyHepatitis B, Chronic +[5] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2021/07/20
Country/TerritoryPhilippinesBrazilMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhengzhou UniversityHenan Genuine Biotech Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesThe First Affiliated Hospital Of Zhengzhou UniversityHRH Pharmaceuticals LtdShanghai Henlius Biotech Inc +[5] 
Inactive CompaniesHenan Sincere Biotech Co LtdBeijing Union Pharmaceutical FactoryZhengzhou University +[4] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyHepatitis B, Chronic +[4] 
Inactive IndicationsAcquired Immunodeficiency Syndrome

Other Information

ATC CodeJ05AF
Related LinksDrugBank